BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 16734503)

  • 21. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches.
    Foss F
    Leuk Lymphoma; 2003; 44 Suppl 3():S55-61. PubMed ID: 15202526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic approaches in cutaneous lymphoma.
    Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
    Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
    Dummer R
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of cutaneous T-cell lymphoma with retinoids.
    Zhang C; Duvic M
    Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapeutic approaches for cutaneous T cell lymphomas.
    Pavlidis A; Piperi C; Papadavid E
    Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel therapies for cutaneous T-cell lymphomas.
    Horwitz SM
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cutaneous lymphomas].
    Schad K; Baumann Conzett K; Cozzio A
    Ther Umsch; 2010 Sep; 67(9):453-64. PubMed ID: 20806174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review of combination therapies for mycosis fungoides.
    Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
    Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of cutaneous T-cell lymphomas.
    Muche JM; Gellrich S; Sterry W
    Semin Cutan Med Surg; 2000 Jun; 19(2):142-8. PubMed ID: 10892717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
    Dummer R; Foss F; Dreno B; Bagot M
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging new therapies for cutaneous T-cell lymphoma.
    Duvic M; Cather JC
    Dermatol Clin; 2000 Jan; 18(1):147-56. PubMed ID: 10626120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.
    Zhang C; Duvic M
    Dermatol Ther; 2003; 16(4):322-30. PubMed ID: 14686975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.